EMEA Anorexiants Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Oct 2020
  • Country Level
  • 350 Pages
  • No of Tables: 297
  • No of Figures: 47

EMEA Anorexiants Market, By Drug Class (Catecholamines Anorexiants, Serotonin Anorexiants), Drug Type (Generics, Branded), Applications (Weight Loss, Obesity, Attention Deficit Hyperactivity Disorder (ADHD), Dravet Syndrome), Prescription Mode (Prescription, OTC), Route of Administration (Oral, Parenteral), End User (Hospitals, Specialty Clinics, Home Healthcare), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, France, U.K., Italy, Netherlands, Spain, Russia, Switzerland, Saudi Arabia, South Africa, Turkey, Austria, UAE, Israel, Norway, Hungary, Lithuania, Kuwait, Ireland, Egypt, Poland, Rest of Europe & Middle East and Africa) Industry Trends and Forecast to 2027

Market Analysis and Insights : EMEA Anorexiants Market

Anorexiants market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 2.7% in the forecast period of 2020 to 2027 and expected to reach USD 146.02 million by 2027. Surge in lifestyle disorders and rising awareness about obesity are the major drivers which propelled the demand of the market in the forecast period.

Anorexiants comprises features such as strategic initiatives by market players that will impact in launching a new product by the manufactures into the market which enhances its demand as well as increasing research and development activities has enhanced the demand of anorexiants drugs. Currently, various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and advanced anorexiants drugs which are expected to provide various other opportunities in the anorexiants market. However, the adoption of alternative treatments and recall of drugs expected to restraint the market growth in the forecast period.

The demand for anorexiants has been increased in both developed as well as in developing countries and the reason behind is the rising prevalence of obesity. The anorexiants market is growing due to a surge in lifestyle disorders, increasing geriatric population, increasing level of stress, rising awareness about obesity among others. The market will grow in the forecasted period due to increasing research and developmental activities, rising disposable income, strategic initiatives by market players, increasing chances of COVID-19 infection to obese patients among others.

The anorexiants market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

EMEA Anorexiants MarketAnorexiants Market Scope and Market Size

Anorexiants market is segmented on the basis of drug class, drug type, applications, prescription mode, route of administration, end user and distribution channel. The growth among segments helps you to analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of drug class, the anorexiants market is segmented into catecholamines anorexiants and serotonin anorexiants. In 2020, catecholamines anorexiants are dominating the market as most of the market players are engaged in manufacturing of catecholamines, moreover it reduces appetite with less side effects.
  • On the basis of drug type, the anorexiants market is segmented into generics and branded. In 2020, branded segment is dominating the market because branded drugs are produces effective results against anorexia.
  • On the basis of applications, the anorexiants market is segmented into weight loss, obesity, attention deficit hyperactivity disorder (ADHD), dravet syndrome. In 2020, weight loss segment dominating the market as anorexiants drugs are primarily intended to reduce the appetite so as to maintain the weight loss in the patients.
  • On the basis of prescription mode, the anorexiants market is segmented into prescription and OTC. In 2020, prescription segment is dominating the market as anorexiants approved for marketing are available only on prescription basis.
  • On the basis of route of administration, the anorexiants market is segmented into oral and parenteral. In 2020, oral segment dominating the market as oral route of drug administration does not required any medical professional; moreover it is a non-invasive drug administration mode.
  • On the basis of end user, the anorexiants market is segmented into hospitals, specialty clinics, and home healthcare. In 2020, hospitals segment is dominating the market because hospitals provide with better diagnosis, moreover trained professional present at hospitals allows correct administration of parenteral anorexiants, in order to produce effective results.
  • On the basis of distribution channel, the anorexiants market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2020, hospital pharmacies segment is dominating the market as prescription based anorexiants drugs are mostly procured from hospital pharmacies.

EMEA ANOREXIANTS MARKETAnorexiants Market Country Level Analysis

The anorexiants market is analysed and market size information is provided by drug class, drug type, applications, prescription mode, route of administration, end user and distribution channel as referenced above.

The country covered in anorexiants market report are Germany, France, U.K., Italy, Netherlands, Spain, Russia, Switzerland, Saudi Arabia, South Africa, Turkey, Austria, UAE, Israel, Norway, Hungary, Lithuania, Kuwait, Ireland, Egypt, Poland, Rest of Europe & Middle East and Africa.

EMEA anorexiants market is growing primarily due to rising prevalence of obesity. The availability of wide variety of drugs and increasing geriatric population are also acting as significant growth factors for the market. The catecholamines anorexiants segment in Germany is dominating the market owing to the increasing demand for effective treatment. France is the fastest-growing region because of the increasing prevalence of obesity and eating disorders. The U.K. holds the third largest market share in the EMEA anorexiants market because of presence of number of market players dealing with the eating disorders and rising children & adult population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as sales, FDA approvals, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global branded and generic drug manufacturers and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rise in Geriatric Population is Propelling the Market Growth

Anorexiants market also provides you with detailed market analysis for every country growth in anorexiants industry with anorexiants sales, impact of advancement in the anorexiants and changes in regulatory scenarios with their support for the anorexiants market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Anorexiants Market Share Analysis

Anorexiants market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to anorexiants market.

The major players covered in the report are VIVUS Inc., Recordati Rare Diseases (A Subsidiary of RECORDATI S.p.A.), Sun Pharmaceutical Industries Ltd., Pfizer Inc., Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Sandoz AG (A Business Division of Novartis AG), Mylan N.V., Bausch Health Companies Inc., Cipla Inc., and Amphastar Pharmaceuticals, Inc. among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch, approval, partnership and agreement are also initiated by the companies’ worldwide which are also accelerating the anorexiants market.

For instance,

  • In February 2020, VIVUS Inc. launched Qsymia in South Korea, for weight loss management. This product launch helped the company to expand its foot print in emerging markets which helped it to overcome the losses arising from established market.
  • In July 2019, Pfizer Inc. signed a collaborative agreement with Mylan N.V., accompany focused on manufacturing of large number of generic drugs involving anorexiants drugs. This collaboration helped the company to expand its market of generic anorexiants, which allowed it to earn more revenue growth.

Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the anorexiants market which also provides the benefit for organisation to improve their offering for anorexiants.

Customization Available: EMEA Anorexiants Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 EMEA ANOREXIANT MARKET, PIPELINE ANALYSIS

TABLE 2 LIST OF ANOREXIANTS DRUGS WHICH ARE SUBJECTED TO PATENT LOSS

TABLE 3 EMEA ANOREXIANTS MARKET, BY DRUG CLASS, 2019-2027 (USD MILLION)

TABLE 4 EMEA ANOREXIANTS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 5 EMEA ANOREXIANTS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 6 EMEA SEROTONIN ANOREXIANTS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 7 EMEA ANOREXIANTS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 8 EMEA ANOREXIANTS MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)

TABLE 9 EMEA GENERICS ANOREXIANTS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 10 EMEA BRANDED ANOREXIANTS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 11 EMEA BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 12 EMEA ANOREXIANTS MARKET, BY APPLICATIONS, 2018-2027 (USD MILLION)

TABLE 13 EMEA ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ANOREXIANTS MARKET, BY APPLICATIONS, 2018-2027 (USD MILLION)

TABLE 14 EMEA DRAVET SYNDROME IN ANOREXIANTS MARKET, BY APPLICATIONS, 2018-2027 (USD MILLION)

TABLE 15 EMEA OBESITY IN ANOREXIANTS MARKET, BY APPLICATIONS, 2018-2027 (USD MILLION)

TABLE 16 EMEA WEIGHT LOSS IN ANOREXIANTS MARKET, BY APPLICATIONS, 2018-2027 (USD MILLION)

TABLE 17 EMEA ANOREXIANTS MARKET, BY PRESCRIPTION MODE, 2018-2027 (USD MILLION)

TABLE 18 EMEA PRESCRIPTION IN ANOREXIANTS MARKET, BY PRESCRIPTION MODE, 2018-2027 (USD MILLION)

TABLE 19 EMEA ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 20 ORAL IN EMEA ANOREXIANTS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 21 EMEA ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 22 PARENTERAL IN EMEA SEROTONIN ANOREXIANTS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 23 EMEA PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 24 EMEA ANOREXIANTS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 25 EMEA HOSPITAL PHARMACIES IN ANOREXIANTS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 26 EMEA RETAIL PHARMACIES IN ANOREXIANTS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 27 EMEA ONLINE PHARMACIES IN ANOREXIANTS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 28 EMEA ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 29 EMEA HOSPITAL PHARMACIES IN ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 30 EMEA RETAIL PHARMACIES IN ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 31 EMEA ONLINE PHARMACIES IN ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 32 EMEA ANOREXIANTS MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)

TABLE 33 EMEA ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 34 EMEA CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 35 EMEA SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 36 EMEA ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 37 EMEA BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 38 EMEA ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 39 EMEA ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 40 EMEA ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 41 EMEA ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 42 EMEA PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 43 EMEA ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 44 EMEA ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 45 GERMANY ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 46 GERMANY CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 47 GERMANY SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 48 GERMANY ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 49 GERMANY BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 50 GERMANY ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 51 GERMANY ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 52 GERMANY ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 53 GERMANY ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 54 GERMANY PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 55 GERMANY ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 56 GERMANY ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 57 FRANCE ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 58 FRANCE CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 59 FRANCE SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 60 FRANCE ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 61 FRANCE BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 62 FRANCE ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 63 FRANCE ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 64 FRANCE ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 65 FRANCE ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 66 FRANCE PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 67 FRANCE ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 68 FRANCE ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 69 U.K. ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 70 U.K. CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 71 U.K. SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 72 U.K. ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 73 U.K. BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 74 U.K. ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 75 U.K. ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 76 U.K. ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 77 U.K. ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 78 U.K. PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 79 U.K. ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 80 U.K. ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 81 ITALY ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 82 ITALY CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 83 ITALY SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 84 ITALY ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 85 ITALY BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 86 ITALY ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 87 ITALY ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 88 ITALY ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 89 ITALY ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 90 ITALY PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 91 ITALY ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 92 ITALY ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 93 NETHERLANDS ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 94 NETHERLANDS CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 95 NETHERLANDS SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 96 NETHERLANDS ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 97 NETHERLANDS BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 98 NETHERLANDS ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 99 NETHERLANDS ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 100 NETHERLANDS ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 101 NETHERLANDS ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 102 NETHERLANDS PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 103 NETHERLANDS ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 104 NETHERLANDS ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 105 SPAIN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 106 SPAIN CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 107 SPAIN SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 108 SPAIN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 109 SPAIN BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 110 SPAIN ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 111 SPAIN ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 112 SPAIN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 113 SPAIN ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 114 SPAIN PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 115 SPAIN ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 116 SPAIN ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 117 RUSSIA ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 118 RUSSIA CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 119 RUSSIA SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 120 RUSSIA ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 121 RUSSIA BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 122 RUSSIA ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 123 RUSSIA ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 124 RUSSIA ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 125 RUSSIA ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 126 RUSSIA PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 127 RUSSIA ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 128 RUSSIA ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 129 SWITZERLAND ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 130 SWITZERLAND CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 131 SWITZERLAND SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 132 SWITZERLAND ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 133 SWITZERLAND BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 134 SWITZERLAND ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 135 SWITZERLAND ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 136 SWITZERLAND ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 137 SWITZERLAND ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 138 SWITZERLAND PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 139 SWITZERLAND ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 140 SWITZERLAND ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 141 SAUDI ARABIA ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 142 SAUDI ARABIA CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 143 SAUDI ARABIA SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 144 SAUDI ARABIA ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 145 SAUDI ARABIA BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 146 SAUDI ARABIA ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 147 SAUDI ARABIA ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 148 SAUDI ARABIA ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 149 SAUDI ARABIA ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 150 SAUDI ARABIA PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 151 SAUDI ARABIA ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 152 SAUDI ARABIA ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 153 SOUTH AFRICA ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 154 SOUTH AFRICA CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 155 SOUTH AFRICA SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 156 SOUTH AFRICA ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 157 SOUTH AFRICA BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 158 SOUTH AFRICA ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 159 SOUTH AFRICA ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 160 SOUTH AFRICA ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 161 SOUTH AFRICA ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 162 SOUTH AFRICA PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 163 SOUTH AFRICA ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 164 SOUTH AFRICA ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 165 TURKEY ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 166 TURKEY CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 167 TURKEY SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 168 TURKEY ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 169 TURKEY BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 170 TURKEY ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 171 TURKEY ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 172 TURKEY ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 173 TURKEYORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 174 TURKEY PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 175 TURKEY ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 176 TURKEYANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 177 AUSTRIA ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 178 AUSTRIA CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 179 AUSTRIA SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 180 AUSTRIA ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 181 AUSTRIA BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 182 AUSTRIA ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 183 AUSTRIA ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 184 AUSTRIA ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 185 AUSTRIA ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 186 AUSTRIA PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 187 AUSTRIA ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 188 AUSTRIA ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 189 UAE ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 190 UAE CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 191 UAE SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 192 UAE ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 193 UAE BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 194 UAE ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 195 UAE ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 196 UAE ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 197 UAE ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 198 UAE PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 199 UAE ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 200 UAE ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 201 ISRAEL ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 202 ISRAEL CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 203 ISRAEL SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 204 ISRAEL ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 205 ISRAEL BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 206 ISRAEL ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 207 ISRAEL ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 208 ISRAEL ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 209 ISRAEL ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 210 ISRAEL PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 211 ISRAEL ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 212 ISRAEL ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 213 NORWAY ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 214 NORWAY CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 215 NORWAY SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 216 NORWAY ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 217 NORWAY BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 218 NORWAY ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 219 NORWAY ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 220 NORWAY ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 221 NORWAY ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 222 NORWAY PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 223 NORWAY ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 224 NORWAY ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 225 HUNGARY ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 226 HUNGARY CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 227 HUNGARY SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 228 HUNGARY ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 229 HUNGARY BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 230 HUNGARY ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 231 HUNGARY ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 232 HUNGARY ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 233 HUNGARY ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 234 HUNGARY PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 235 HUNGARY ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 236 HUNGARY ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 237 LITHUANIA ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 238 LITHUANIA CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 239 LITHUANIA SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 240 LITHUANIA ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 241 LITHUANIA BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 242 LITHUANIA ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 243 LITHUANIA ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 244 LITHUANIA ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 245 LITHUANIA ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 246 LITHUANIA PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 247 LITHUANIA ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 248 LITHUANIA ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 249 KUWAIT ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 250 KUWAIT CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 251 KUWAIT SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 252 KUWAIT ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 253 KUWAIT BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 254 KUWAIT ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 255 KUWAIT ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 256 KUWAIT ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 257 KUWAIT ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 258 KUWAIT PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 259 KUWAIT ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 260 KUWAIT ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 261 IRELAND ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 262 IRELAND CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 263 IRELAND SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 264 IRELAND ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 265 IRELAND BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 266 IRELAND ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 267 IRELAND ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 268 IRELAND ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 269 IRELAND ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 270 IRELAND PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 271 IRELAND ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 272 IRELAND ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 273 EGYPT ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 274 EGYPT CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 275 EGYPT SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 276 EGYPT ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 277 EGYPT BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 278 EGYPT ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 279 EGYPT ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 280 EGYPT ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 281 EGYPT ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 282 EGYPT PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 283 EGYPT ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 284 EGYPT ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 285 POLAND ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 286 POLAND CATECHOLAMINES ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 287 POLAND SEROTONIN ANOREXIANTS IN ANOREXIANTS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION)

TABLE 288 POLAND ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 289 POLAND BRANDED IN ANOREXIANTS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 290 POLAND ANOREXIANTS MARKET, BY APPLICATIONS 2018-2027 (USD MILLION)

TABLE 291 POLAND ANOREXIANTS MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)

TABLE 292 POLAND ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 293 POLAND ORAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 294 POLAND PARENTERAL ROUTE OF ADMINISTRATION IN ANOREXIANTS MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 295 POLAND ANOREXIANTS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 296 POLAND ANOREXIANTS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 297 REST OF EMEA ANOREXIANTS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions